Literature DB >> 23068291

Thromboembolism in patients with nonvalvular atrial fibrillation: comparison between Asian and Western countries.

Hiroshi Inoue1.   

Abstract

Atrial fibrillation (AF) is one of the common cardiac arrhythmias and is responsible for increased mortality and various morbidities. The prevalence, mortality, morbidity, and treatment strategy for AF might differ between Western countries and Asian countries including Japan. AF prevalence in elderly subjects (≥ 80 years old) is relatively low in Japan, Korea, and Taiwan as compared with Western countries. In contrast, the prevalence in mainland China is intermediate between Japan and Western countries. CHADS(2) score and its new version, CHA(2)DS(2)-VASc score, are useful to predict subsequent thromboembolic events in Japanese AF patients. Guidelines in Western countries recommend target anticoagulation levels for prevention of thromboembolic and major hemorrhagic events at prothrombin time international normalized ratio (PT-INR) of 2-3. However, relatively lower PT-INR levels could be suitable for prevention of these events among patients with nonvalvular AF in Japan and China. New oral anticoagulants have been launched in Japan as an alternative to warfarin. The management strategy for AF patients needs to be modified based on the data obtained from Japanese patients.
Copyright © 2012 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23068291     DOI: 10.1016/j.jjcc.2012.08.012

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  4 in total

1.  Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry.

Authors:  Jean-Pierre Bassand; Saverio Virdone; Marc Badoz; Freek W A Verheugt; A John Camm; Frank Cools; Keith A A Fox; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Werner Hacke; Gloria Kayani; Frank Misselwitz; Karen S Pieper; Alexander G G Turpie; Martin van Eickels; Ajay K Kakkar
Journal:  Blood Adv       Date:  2021-02-23

2.  When Should Antiplatelet Agents Be Resumed After Successful Endoscopic Hemostasis in Patients with Peptic Ulcer Bleeding?

Authors:  Jung-Wook Kim; Hyun Jin Park; Jae-Young Jang; Chi Hyuk Oh; Jae-Jun Shim; Chang Kyun Lee; Young Woon Chang
Journal:  Dig Dis Sci       Date:  2016-02-05       Impact factor: 3.199

3.  Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.

Authors:  Jonathan P Piccini; Anne S Hellkamp; Yuliya Lokhnygina; Manesh R Patel; Frank E Harrell; Daniel E Singer; Richard C Becker; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Scott D Berkowitz; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf
Journal:  J Am Heart Assoc       Date:  2014-04-22       Impact factor: 5.501

4.  Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.

Authors:  Jean-Pierre Bassand; Gabriele Accetta; Wael Al Mahmeed; Ramon Corbalan; John Eikelboom; David A Fitzmaurice; Keith A A Fox; Haiyan Gao; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Gloria Kayani; Karen Pieper; Alexander G G Turpie; Martin van Eickels; Freek W A Verheugt; Ajay K Kakkar
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.